Zoetis Services LLC

Pfizer Corporation

Zoetis LLC

Donald Wayne Mann

Andrea Joy Gonzales

Mark J Mitton-Fry

Jerry W Bowman

Matthew Joseph Birchmeier

Pamela J Berlinski

Steven Glenn Kamerling

Joseph P Lyssikatos

Scott J Hecker

Steven Alan Dunham

Christopher Blair Cooper

Gary Francis Bammert

James Taylor Curry

Robert B McCall

William R Humphrey

Mark Joseph Mitton-Fry

Pamela Jo Berlinski

Jerry Wayne Bowman

An IL-31 dog pruritus model is provided. This model comprises administering canine IL-31 to dogs to produce a pruritic response; quantitatively measuring pruritic responses in the dogs which were administered canine IL-31; administering a candidate dog IL-31 inhibitor; and assessing the effectiveness of the candidate dog IL-31 inhibitor in reducing prurtic behavior in the treated dogs by challenging the dogs with canine IL-31 following the administration of the candidate dog IL-31 inhibitor.

IL-31 dog pruritus model

Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.

Pyrrolo[2,3-D]pyrimidine compounds

Pyrrolo[2,3-d]pyrimidine compounds

Described herein is pyrrolo{2,3-}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.

[object Object]

A compound of the formula ##STR1## wherein a, V, X, Y, Z, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined above, useful in (a) the treatment of myelosuppression including suppression associated with cancer chemotherapy as well as activation of the immune system for the treatment of cancer or (b) prevention and treatment of viral, fungal, bacterial and parasitic infectious diseases.

2-Aminobenzazapine derivatives

Growing community of inventors

Jewett City, CT, United States of America

Donald Wayne Mann